866-997-4948(US-Canada Toll Free)

Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 54 Pages


GlobalData, the industry analysis specialist’s new report, “Anti-Hypertension Therapeutics - Pipeline Assessment And Market Forecasts to 2017” is an essential source of information and analysis on the global hypertension market. The report identifies the key trends shaping and driving the global hypertension market. The report also provides insight on the competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global hypertension market. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. 

GlobalData estimated the global hypertension market, in 2009, at $36.9 billion indicating a cumulative annual growth rate (CAGR) of 5.3% between 2001 and 2009. The growth in the market can mainly attribute to the growth in the sales of angiotensin renin blockers, the only therapeutic class that has antihypertensive drugs under patent protection. Though ARBs are less effective compared to other drugs such as beta-blockers and calcium channel blockers, they became the frontline treatment for patients diagnosed with hypertension. In addition, the prevalence of hypertension was one of the major factors responsible for the growth of hypertension market between 2001 and 2009. Due to expected patent expiry of blockbusters such as Diovan, Cozaar and Avapro, the market is forecast to decline at a CAGR of -5.2% between 2009 and 2017. 

GlobalData analyzed that current competition in the hypertension market is very strong. Drugs acting on the renin angiotensin system dominated the hypertension market in 2009. The patent expiry of key blockbusters and uncertain success of molecule in Phase II and Phase III of development, leads to diminish the hypertension market between 2009 and 2017. The hypertension pipeline is strong. Though there are over 90 molecules in various stages of pipeline for hypertension, majority of them are either me-too products or product extensions of the marketed drugs. More than 34 molecules in the pipeline are me-too drugs and 28 molecules are product extensions of the marketed blockbusters. Big pharmaceutical companies marketing major ARBs are in a race to capture the highest market share in the hypertension market. 

Scope

The scope of the report includes:

  • Annualized global hypertension market revenues data from 2001 to 2009, forecast forward for 8 years to 2017.
  • Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The first-in-class drugs act through new mechanisms of action such as eNOS (Endothelial Nitric Oxide Synthase) couplers, SGLT2 inhibitors, endothelin antagonists, PPAR-gamma agonists.
  • Analysis of the current and future market competition in the global hypertension market. Key future market players covered are Novartis Ag, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceuticals, Daiichi Sankyo Co. Ltd, GlaxoSmithKline Plc, and sanofi-aventis.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with hypertension market.
Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global hypertension market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global hypertension market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global hypertension market landscape? - Identify, understand and capitalize.
Table of Content

1 Table of contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Anti-Hypertension- Introduction 6
2.1 GlobalData Pipeline Report Guidance 6

3 Anti-Hypertension Therapeutics Market: Market Characterization 7
3.1 Overview 7
3.2 Anti-Hypertension Therapeutics Market Size 7
3.3 Anti-Hypertension Therapeutics market Forecast and CAGR 8
3.4 Drivers and Barriers for Anti-Hypertension Therapeutics Market 9
3.4.1 Drivers for Anti-Hypertension Therapeutics Market 9
3.4.2 Restraints for Anti-Hypertension Therapeutics Market 9
3.5 Opportunity and Unmet Need 10
3.5.1 Unmet Needs 10
3.5.2 Impact Analysis of Unmet Needs 10
3.6 Key Takeaway 11

4 Anti-Hypertension Therapeutics Market: Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in the Anti-Hypertension Market 13
4.3.1 Angiotensin II Receptor Blockers 13
4.3.2 Angiotensin Converting Enzyme Inhibitors 16
4.3.3 Diuretics 18
4.3.4 Beta Blockers 20
4.3.5 Calcium Channel Blockers 22
4.4 Key Takeaway 25

5 Anti-Hypertension Therapeutics Market: Pipeline Assessment 26
5.1 Overview 26
5.2 Strategic Pipeline Assessment 26
5.2.1 Technology Trends Analytic Framework 26
5.3 Hypertension Promising Drugs Under Clinical Development 28
5.4 Molecule Profile for Promising Drugs under Clinical Development 28
5.4.1 SPP635 28
5.4.2 Actos (pioglitazone) 29
5.5 Anti-Hypertension Therapeutics Market Clinical Pipeline by Mechanism of Action 30
5.6 Hypertension Pipeline Pipeline by Clinical Phases of Development 31
5.6.1 Hypertension Regulatory Filing and Phase III Clinical Pipeline 32
5.6.2 Hypertension Phase II Clinical Pipeline 34
5.6.3 Hypertension Phase I Clinical Pipeline 35
5.6.4 Hypertension Preclinical Pipeline 36
5.6.5 Hypertension Discovery Pipeline 36
5.7 Key Takeaway 36

6 Anti-Hypertension Therapeutics market: Implications for Future Market Competition 37

7 Anti-Hypertension Therapeutics Market: Future Players in Anti-Hypertension Therapeutics market 38

7.1 Introduction 38
7.2 Novartis AG 38
7.2.1 Company Overview 38
7.2.2 Business Description 39
7.2.3 Hypertension Portfolio 39
7.3 Merck & Co. Inc. 41
7.3.1 Overview 41
7.3.2 Business Description 41
7.4 Daiichi Sankyo Co. Ltd 42
7.4.1 Company Overview 42
7.4.2 Business Description 43
7.4.3 Hypertension Portfolio 43
7.5 Boehringer Ingelheim GmbH 44
7.5.1 Company Overview 44
7.5.2 Business Description 44
7.5.3 Hypertension Portfolio 45
7.6 GlaxoSmithKline 45
7.6.1 Company Overview 45
7.6.2 Business Description 45
7.6.3 Hypertension Portfolio 46
7.7 Sanofi-Aventis 46
7.7.1 Company Overview 46
7.7.2 Business Description 47
7.7.3 Hypertension Portfolio 47

8 Anti-Hypertension Therapeutics Market: Appendix 48
8.1 Definitions 48
8.2 Acronyms 48
8.3 Research Methodology 49
8.3.1 Coverage 49
8.3.2 Secondary Research 49
8.3.3 Forecasting 50
8.3.4 Primary Research 53
8.3.5 Expert Panel validation 53
8.4 Contact Us 53
8.5 Disclaimer 53
8.6 Sources 54

List of Table


Table 1: Anti-Hypertension Therapeutics Market, Global, Revenue ($bn) and Growth Rate (%), 2001-2009 8
Table 2: Anti-Hypertension Therapeutics Market, Global, Forecast Revenues ($bn) and Growth Rate(%), 2009-2017 8
Table 3: Anti-Hypertension Market, Global, Diovan, Adverse Reactions 14
Table 4: Anti-Hypertension Therapeutics Market, Global, Cozaar, Adverse Reactions 16
Table 5: Anti-Hypertension Therapeutics Market, Global, Vasotec, Adverse Reactions 17
Table 6: Anti-Hypertension Therapeutics Market, Global, Lotensin, Adverse Reactions 18
Table 7: Anti-Hypertension Therapeutics, Global, Majorly Marketed Products Comparison, 2010 24
Table 8: Anti-Hypertension Therapeutics Market, Global, Most Promising Drugs Under Clinical Development, 2010 28
Table 9: Anti-Hypertension Therapeutics, Global, Regulatory and Phase III Pipeline, 2010 32
Table 10: Anti-Hypertension Therapeutics, Phase II Pipeline, 2010 34
Table 11: Anti-Hypertension Therapeutics, Phase I Pipeline, 2010 35
Table 12: Anti-Hypertension Therapeutics, Preclinical Pipeline, 2010 36
Table 13: Anti-Hypertension Therapeutics, Discovery Stage Pipeline, 2010 36
Table 14: Novartis, Marketed Anti-Hypertension Products, 2010 39
Table 15: Novartis, Anti-Hypertension Drugs Pipeline, 2010 40
Table 16: Merck & Co. Marketed Anti-Hypertension Products, 2010 41
Table 17: Merck & Co. Anti-Hypertension Drugs Pipeline, 2010 42
Table 18: Daiichi Sankyo, Marketed Anti-Hypertension Products, 2010 43
Table 19: Daiichi Sankyo, Anti-Hypertension Drugs Pipeline, 2010 44
Table 20: Boehringer Ingelheim Marketed Anti-Hypertension Products, 2010 45
Table 21: Boehringer Ingelheim Anti-Hypertension Drugs Pipeline, 2010 45
Table 22: GlaxoSmithKline Marketed Anti-Hypertension Products, 2010 46
Table 23: GlaxoSmithKline Anti-Hypertension Drugs Pipeline, 2010 46
Table 24: Sanofi-Aventis Marketed Anti-Hypertension Products, 2010 47
Table 25: Sanofi-Aventis Anti-Hypertension Drugs Pipeline, 2010 47

List of Chart


Figure 1: Anti-Hypertension Therapeutics Market, Global, Revenue ($bn), 2001-2009 7
Figure 2: Anti-Hypertension Therapeutics Market, Global, Forecast Revenues ($bn), 2009-2017 8
Figure 3: Anti-Hypertension Therapeutics Market, Global, Opportunity and Unmet Need 11
Figure 4: Anti-Hypertension Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Products, 2010 13
Figure 5: Technology Trends Analytic Framework of Anti-Hypertension Pipeline, 2010 27
Figure 6: Technology Trends Analytic Framework of Anti-Hypertension Pipeline - Description, 2010 27
Figure 7: Anti-Hypertension Therapeutics Market, Clinical Pipeline by Mechanism of Action (%), 2010 30
Figure 8: Anti-Hypertension Therapeutics Market, Pipeline by Phase of Clinical Development (%), 2010 31
Figure 9: Anti-Hypertension Therapeutics Market, Global, Implications for Future Market Competition, 2010 37
Figure 10: Anti-Hypertension Therapeutics Market, Global, Clinical Pipeline by Company, 2010 38
Figure 11: GlobalData Market Forecasting Model 52

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *